CAR T Therapy in Non-Hodgkin Lymphoma: Kelly Garvin, BSN, RN


The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Kelly Garvin, MA, BSN, RN, Moffitt Cancer Center, about the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.

Five FDA-approved CAR T-cell products are currently available for patients with certain hematologic malignancies, with even more indications expected in the future. For most patients with diffuse large B-cell lymphoma, treatment with immunotherapy and the chemotherapy regimen comprised of rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone can be curative; however, outcomes remain poor for those who do not respond to this approach, according to Garvin.

Currently, ongoing trials are examining CAR T-cell therapy vs standard of care in this patient population, to see whether the former modality can yield better outcomes, Garvin notes. If patients with poor prognostic factors can be identified early enough to utilize CAR T-cell therapy, outcomes could potentially be improved, Garvin concludes.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.